Cardiovascular Protection of Nephropathic Male Patients by Oral Food Supplements.

Cardiovasc Ther

PHYTOLAB (Pharmaceutical, Cosmetic, Food Supplement, Technology and Analysis)-DiSIA, University of Florence, Via U. Schiff, 6, 50019 Sesto Fiorentino, Italy.

Published: September 2020


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Nephropathic patients show elevated cardiovascular morbidity and mortality compared to the general population. In order to delve deeper into the understanding of this phenomenon, it is necessary to recognize risk factors that are distinctive to the uremic state, such as oxidative stress and chronic low-grade inflammation. Moreover, gender differences have been reported in nephrology, as it has been observed that chronic kidney disease has higher prevalence in males than in females. The use of an oral food supplement (OFS) containing natural active compounds from L., Garcinia cambogia, L., artichoke, and L. which are virtually devoid from side effects, but rich in antioxidant and antiradical properties, could represent a valid therapeutic adjunct in the clinical management of nephropathic patients. Moreover, quantitative analysis performed on such compounds showed that they expressed good total antioxidant (7.28 gallic acid equivalents) and antiradical activity (above 80%). In this study, 23 male nephropathic patients and 10 age and body composition parameter matched healthy males (control group) were enrolled and took 3 cps/day of OFS for 5 weeks. At the end of the study, the nephropathic patient group showed a statistically significant reduction in the following laboratory parameters: total cholesterol (TC) ( = 0.044), atherogenic index TC/high-density lipoprotein cholesterol ( = 0.010), inflammatory parameters (C-reactive protein, = 0.048, and erythrocyte sedimentation rate, = 0.019), systolic ( = 0.044), and diastolic arterial blood pressure ( = 0.003). Regarding body composition, there was an increase in total body water % ( = 0.035) with redistribution of extracellular water % ( = 0.030) and intracellular water % ( = 0.049). In the control group, there was a reduction in fat mass % ( = 0.017) and extracellular water % ( = 0.047). Therefore, this OFS may represent a valid adjunct therapy to counteract comorbidities related to uremia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334761PMC
http://dx.doi.org/10.1155/2020/1807941DOI Listing

Publication Analysis

Top Keywords

nephropathic patients
12
oral food
8
represent valid
8
body composition
8
control group
8
extracellular water
8
nephropathic
5
cardiovascular protection
4
protection nephropathic
4
nephropathic male
4

Similar Publications

Therapeutic strategies in cystinosis: A focus on cysteamine and beyond.

Exp Mol Pathol

September 2025

Azienda Sanitaria Locale di Salerno, 84124 Salerno, Italy.

Cystinosis is a autosomal recessive lysosomal storage disorder caused by mutations in the CTNS gene, which encodes cystinosin, a cystine transporter. The defective function of cystinosin leads to cystine accumulation in the lysosome, resulting in progressive multi-organ damage. Cystinosis manifests early in life, with nephropathic cystinosis typically presenting in infancy with renal Fanconi syndrome, leading to chronic kidney disease and end-stage renal disease if untreated.

View Article and Find Full Text PDF

Background: Cystinosis is a rare genetic disorder, with the majority of patients suffering from infantile nephropathic cystinosis, the most severe form. If left untreated, cystinosis causes serious morbidity, initially through progressive kidney and eye disease, followed by systemic and multiorgan involvement, ultimately leading to premature death. In this systematic review, we summarize the evidence for cystinosis to support the development of an evidence-based clinical practice guideline (SELECT - S3 guideline for cystinosis).

View Article and Find Full Text PDF

Cystinosis is a rare systemic disease characterized by the accumulation of cystine in tissues, leading to multi-organ damage. Infantile nephropathic cystinosis is the dominant and severe form of cystinosis with critical renal manifestations that require kidney transplantation at an early age if left untreated. Cysteamine, the lifelong cystine-depleting therapy, is the mainstay treatment of nephropathic cystinosis.

View Article and Find Full Text PDF

SARS-CoV-2 and chronic kidney disease: challenges and future directions.

Curr Opin Immunol

October 2025

Department of Medicine, Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland; Faculty of Medicine, University of Basel, 4056 Basel, Switzerland; Division of Infectious Diseases, Ente Ospedaliero Cantonale (EOC), Ospedale Regionale Bellinzona e Valli, 6500 Bellinzona, Switzerland.

Patients with chronic kidney disease (CKD), especially those with end-stage kidney disease on dialysis or kidney transplant recipients (KTRs), are highly susceptible to infections, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic disproportionately affected this vulnerable population, leading to increased morbidity and mortality. Immune dysfunction in CKD patients contributes to a suboptimal defense against infections and a reduced response to SARS-CoV-2 vaccinations.

View Article and Find Full Text PDF

Chronic kidney disease is a very common condition, often underdiagnosed, and a major risk factor for cardiovascular complications and premature death. There is an increasing interest in scientific society in implementing effective treatments for kidney disease to slow progression. In the last decades angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) have been the only drugs recommended for chronic kidney disease.

View Article and Find Full Text PDF